Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania. more
Time Frame | APRE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.71% | -2.27% | -0.57% |
1-Month Return | -3.16% | -3.96% | 1.21% |
3-Month Return | 1.43% | -9.7% | 7.57% |
6-Month Return | -24.47% | -3.37% | 11.45% |
1-Year Return | -18.49% | 3.71% | 28.48% |
3-Year Return | -95.77% | 3.8% | 29.52% |
5-Year Return | -99.57% | 39.78% | 90.66% |
10-Year Return | -99.22% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 583.23K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 170.25K | 229.61K | 271.68K | 186.44K | 7.05K | [{"date":"2019-12-31","value":62.67,"profit":true},{"date":"2020-12-31","value":84.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.63,"profit":true},{"date":"2023-12-31","value":2.6,"profit":true}] |
Gross Profit | (170.25K) | (229.61K) | (271.68K) | (186.44K) | 576.18K | [{"date":"2019-12-31","value":-29.55,"profit":false},{"date":"2020-12-31","value":-39.85,"profit":false},{"date":"2021-12-31","value":-47.15,"profit":false},{"date":"2022-12-31","value":-32.36,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | 98.79% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 29.54M | 52.81M | 37.45M | 37.37M | 16.05M | [{"date":"2019-12-31","value":55.94,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":70.91,"profit":true},{"date":"2022-12-31","value":70.77,"profit":true},{"date":"2023-12-31","value":30.39,"profit":true}] |
Operating Income | (31.04M) | (52.15M) | (38.04M) | 38.18M | (15.47M) | [{"date":"2019-12-31","value":-81.31,"profit":false},{"date":"2020-12-31","value":-136.59,"profit":false},{"date":"2021-12-31","value":-99.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-40.52,"profit":false}] |
Total Non-Operating Income/Expense | 3.14M | (444.95K) | 320.70K | (74.84M) | 2.34M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-14.17,"profit":false},{"date":"2021-12-31","value":10.22,"profit":true},{"date":"2022-12-31","value":-2384.06,"profit":false},{"date":"2023-12-31","value":74.61,"profit":true}] |
Pre-Tax Income | (28.06M) | (53.48M) | (37.13M) | (112.66M) | (14.29M) | [{"date":"2019-12-31","value":-2805980700,"profit":false},{"date":"2020-12-31","value":-5347881200,"profit":false},{"date":"2021-12-31","value":-3712730300,"profit":false},{"date":"2022-12-31","value":-11266202700,"profit":false},{"date":"2023-12-31","value":-1428675600,"profit":false}] |
Income Taxes | (1.65M) | 437.99K | (590.73K) | 112.21M | (2.00) | [{"date":"2019-12-31","value":-1.47,"profit":false},{"date":"2020-12-31","value":0.39,"profit":true},{"date":"2021-12-31","value":-0.53,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (26.41M) | (53.92M) | (36.54M) | (224.88M) | (14.29M) | [{"date":"2019-12-31","value":-2640506200,"profit":false},{"date":"2020-12-31","value":-5391680200,"profit":false},{"date":"2021-12-31","value":-3653657600,"profit":false},{"date":"2022-12-31","value":-22487538700,"profit":false},{"date":"2023-12-31","value":-1428675400,"profit":false}] |
Income From Continuous Operations | (28.06M) | (53.48M) | (37.13M) | (112.66M) | (13.29M) | [{"date":"2019-12-31","value":-2805980700,"profit":false},{"date":"2020-12-31","value":-5347881200,"profit":false},{"date":"2021-12-31","value":-3712730300,"profit":false},{"date":"2022-12-31","value":-11266202700,"profit":false},{"date":"2023-12-31","value":-1328564400,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (26.41M) | (53.92M) | (36.54M) | (224.88M) | (14.29M) | [{"date":"2019-12-31","value":-2640506200,"profit":false},{"date":"2020-12-31","value":-5391680200,"profit":false},{"date":"2021-12-31","value":-3653657600,"profit":false},{"date":"2022-12-31","value":-22487538700,"profit":false},{"date":"2023-12-31","value":-1428675600,"profit":false}] |
EPS (Diluted) | (118.91) | (50.80) | (35.00) | (30.12) | (3.99) | [{"date":"2019-12-31","value":-11891,"profit":false},{"date":"2020-12-31","value":-5080,"profit":false},{"date":"2021-12-31","value":-3500,"profit":false},{"date":"2022-12-31","value":-3012,"profit":false},{"date":"2023-12-31","value":-399,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
APRE | |
---|---|
Cash Ratio | 7.22 |
Current Ratio | 7.28 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APRE | |
---|---|
ROA (LTM) | -30.26% |
ROE (LTM) | -50.11% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APRE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APRE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 13.61 |
P/B | 0.79 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.35 |
Aprea Therapeutics Inc (APRE) share price today is $3.195
Yes, Indians can buy shares of Aprea Therapeutics Inc (APRE) on Vested. To buy Aprea Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APRE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Aprea Therapeutics Inc (APRE) via the Vested app. You can start investing in Aprea Therapeutics Inc (APRE) with a minimum investment of $1.
You can invest in shares of Aprea Therapeutics Inc (APRE) via Vested in three simple steps:
The 52-week high price of Aprea Therapeutics Inc (APRE) is $8.85. The 52-week low price of Aprea Therapeutics Inc (APRE) is $2.15.
The price-to-earnings (P/E) ratio of Aprea Therapeutics Inc (APRE) is
The price-to-book (P/B) ratio of Aprea Therapeutics Inc (APRE) is 0.79
The dividend yield of Aprea Therapeutics Inc (APRE) is 0.00%
The market capitalization of Aprea Therapeutics Inc (APRE) is $19.57M
The stock symbol (or ticker) of Aprea Therapeutics Inc is APRE